Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Anti-Glutamate Antibodies on the Content of IL-4 and IL-10 in Brain Structures in Aged Mice with Induced Memory Impairment.

Bulletin of experimental biology and medicine·2026
Same author

Effect of Glutamate Antibodies on ASCL1 Gene Expression in Aging Mice with Spatial Memory Impairment Caused by Amyloid Fibrils of the Proinflammatory Protein S100A9.

Bulletin of experimental biology and medicine·2025
Same author

Antibodies to Glutamate Reduce the IL-6 Content in Cerebral Structures in Mice with Age-Related Memory Impairment.

Bulletin of experimental biology and medicine·2024
Same author

Effect of Glutamate Antibody F(ab)2 Fragments on Memory Changes in Aged C57BL/6 Mice.

Bulletin of experimental biology and medicine·2023
Same author

[Ocular myasthenia gravis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023
Same author

Cerebral Expression of the Neuregulin-1 Gene NRG1 during Induced Spatial Memory Impairment and Its Reversal in Aging Mice.

Bulletin of experimental biology and medicine·2022

Related Experiment Video

Updated: Jul 6, 2026

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

[Myasthenic myopathy].

A G Sanadze, D V Sidnev, O I Galkina

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |April 2, 2008
    PubMed
    Summary

    This study suggests a distinct "myasthenic myopathy" in patients with thymoma or late-onset myasthenia gravis. These findings link specific clinical symptoms to electrophysiological and immunological markers, differentiating them from other myasthenia forms.

    Related Experiment Videos

    Last Updated: Jul 6, 2026

    Measuring Neuromuscular Junction Functionality
    10:40

    Measuring Neuromuscular Junction Functionality

    Published on: August 6, 2017

    Area of Science:

    • Neurology
    • Immunology
    • Clinical Medicine

    Background:

    • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
    • Thymoma and late-onset MG present unique clinical and pathological characteristics.
    • The role of anti-Titin antibodies and specific clinical patterns in these subgroups requires further elucidation.

    Purpose of the Study:

    • To investigate clinical, electrophysiological, and immunological parameters in myasthenic patients with thymoma and those with late-onset or early-onset MG without thymoma.
    • To identify specific clinical symptoms associated with thymoma and late-onset MG.
    • To explore the correlation between clinical findings, electrophysiological data, and anti-Titin antibody levels.

    Main Methods:

    • Clinical assessment of symptoms including chewing, bulbar disturbances, and muscle weakness (neck, deltoideus).
    • Electrophysiological testing to analyze motor unit potential duration.
    • Serological testing for specific anti-Titin antibodies.
    • Comparison of findings across three patient groups: MG with thymoma, late-onset MG without thymoma, and early-onset MG without thymoma.

    Main Results:

    • Prevalence of chewing and bulbar disturbances, neck and deltoideus muscle weakness was observed in patients with thymoma and late-onset MG without thymoma.
    • These clinical features correlated with the absence of changes in minimal motor unit potential duration after proserine injection.
    • An increased level of anti-Titin antibodies was noted in these patient subgroups.

    Conclusions:

    • The study suggests the presence of a distinct condition, termed "myasthenic myopathy," in patients with myasthenia gravis comorbid with thymoma.
    • This
    • myasthenic myopathy
    • is also suggested in patients experiencing late-onset myasthenia gravis without thymoma.
    • Clinical, electrophysiological, and immunological data collectively support this hypothesis, differentiating these patient groups.